Valuation: Grifols SA

Market Cap 653.59Cr 729.78Cr 601.2Cr 544.74Cr 1.02TCr 69TCr 1.04TCr 7.17TCr 2.88TCr 36TCr 2.74TCr 2.68TCr 1,15000Cr P/E 2026 *
13.8x
P/E 2027 * 10.8x
Enterprise Value 1.48TCr 1.65TCr 1.36TCr 1.23TCr 2.3TCr 1,56500Cr 2.34TCr 16TCr 6.5TCr 82TCr 6.18TCr 6.05TCr 2,59600Cr EV / Sales 2026 *
1.92x
EV / Sales 2027 * 1.79x
Free-Float
79.65%
Yield 2026 *
2.51%
Yield 2027 * 3.09%
Manager TitleAgeSince
Chief Executive Officer 58 01/04/2024
Director of Finance/CFO 49 16/09/2024
Compliance Officer 54 01/01/2014
Director TitleAgeSince
Chairman 76 25/01/2010
Director/Board Member 70 13/04/2000
Director/Board Member 62 24/05/2015
Change 5-day change 1-year change 3-year change Capi.($)
+3.19%+11.31%+64.28%+155.66% 1,26300Cr
-0.73%+3.56%+44.65%+83.74% 66TCr
+1.41%+3.24%+35.25%+106.98% 52TCr
-1.70%+0.15%+53.03%+66.74% 39TCr
+2.18%+2.93%+73.90%+45.38% 37TCr
-1.97%+3.17%+32.18%+55.35% 31TCr
-1.59%+6.75%+10.98%+32.43% 29TCr
+1.15%+6.09%+56.15%+78.66% 25TCr
+3.06%+9.38%+42.48%+112.84% 21TCr
Average +0.05%+5.90%+45.88%+81.98% 47.35TCr
Weighted average by Cap. -0.12%+6.60%+50.00%+98.62%

Financials

2026 *2027 *
Net sales 767.07Cr 856.49Cr 705.58Cr 639.32Cr 1.2TCr 81TCr 1.22TCr 8.41TCr 3.38TCr 43TCr 3.21TCr 3.15TCr 1,34900Cr 816.62Cr 911.81Cr 751.16Cr 680.61Cr 1.27TCr 87TCr 1.3TCr 8.96TCr 3.6TCr 46TCr 3.42TCr 3.35TCr 1,43600Cr
Net income 53Cr 60Cr 49Cr 45Cr 83Cr 5.66TCr 85Cr 586Cr 235.24Cr 2.98TCr 223.86Cr 219.1Cr 9.4TCr 70Cr 79Cr 65Cr 59Cr 109.78Cr 7.47TCr 111.83Cr 772.94Cr 310.28Cr 3.93TCr 295.27Cr 288.99Cr 12TCr
Net Debt 822.34Cr 918.2Cr 756.42Cr 685.38Cr 1.28TCr 87TCr 1.31TCr 9.02TCr 3.62TCr 46TCr 3.45TCr 3.37TCr 1,44600Cr 808.43Cr 902.67Cr 743.63Cr 673.79Cr 1.26TCr 86TCr 1.28TCr 8.87TCr 3.56TCr 45TCr 3.39TCr 3.32TCr 1,42200Cr
Logo Grifols SA
Grifols, S.A. specializes in the research, development, manufacturing and marketing of therapeutic products and medical devices for use in hospitals and medical analysis laboratories. Net sales break down by family of products and services as follows: - products derived from plasma (86.2%): products for use by the pharmaceutical and biotechnology industries; - diagnostic machines and reagents (8.5%): in vitro hemophilic diagnostic equipment, coagulation analyzers, infectious serology reagents, etc. for use primarily by blood banks and transfusion centers; - hospital products (2.1%): non-biological surgical products, radiology and nutritional products, etc. for use by hospital pharmacies; - other (3.2%): primarily intermediate biological products and subcontracted manufacturing services. Net sales are distributed geographically as follows: Spain (5.6%), European Union (15.9%), the United States and Canada (56.5%) and other (22%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Grifols SA